专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110243979A1 Method of Transcutaneous Immunization Using Antigen 审中-公开
标题翻译：使用抗原经皮免疫的方法
公开(公告)号：US20110243979A1
公开(公告)日：2011-10-06
申请号：US13011071
申请日：2011-01-21
申请人： Gregory M. Glenn , Carl R. Alving
发明人： Gregory M. Glenn , Carl R. Alving
IPC分类号： A61K39/00 , A61K39/12 , A61K39/02 , A61K39/108 , A61K39/07 , A61P37/04 , A61P31/12 , A61P31/16 , A61P31/14 , A61P31/10 , A61P33/00 , A61P31/04 , A61M5/00 , A61M37/00 , A61N1/30
CPC分类号： A61K39/39 , A61K9/0019 , A61K9/0021 , A61K39/00 , A61K2039/54 , A61K2039/55544 , C12N2760/16134
摘要： Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response. Use of skin-active adjuvants is preferred. Although perforation of intact skin is not required, superficial penetration or micropenetration of the skin can act as an enhancer; similarly, hydration may enhance the immune response. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigen and adjuvant. The formulation may initiate processes such as antigen uptake, processing, and presentation; Langerhans cell activation, migration from the skin to other immune organs, and differentiation to mature dendritic cells; contacting antigen with lymphocytes bearing cognate antigen receptors on the cell surface and their stimulation; and combinations thereof. Systemic and/or regional immunity may be induced; immune responses that result in prophylaxis and/or therapeutic treatments are preferred. Antigen and adjuvant activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens and adjuvants which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a liquid formulation, patches or other medical devices may be used to deliver antigen for immunization.
摘要翻译：经皮免疫可以通过角质层将免疫系统的抗原递送到皮肤的真皮层，而不会物理或化学地渗透到真皮层。该递送系统诱导抗原特异性免疫应答。优选使用皮肤活性佐剂。虽然不需要完整皮肤的穿孔，但皮肤的表面渗透或微穿透可以作为增强剂; 类似地，水合可以增强免疫应答。该系统在表皮施用含有一种或多种抗原和佐剂的制剂后可以诱导抗原特异性免疫效应物。制剂可以引发诸如抗原摄取，加工和表达的过程; 朗格汉斯细胞活化，从皮肤迁移到其他免疫器官，并分化成成熟树突状细胞; 使抗原与淋巴细胞接触细胞表面的同源抗原受体及其刺激; 及其组合。可能诱发全身和/或区域免疫; 导致预防和/或治疗性治疗的免疫应答是优选的。制剂中的抗原和佐剂活性可以在相同的分子中发现，两个或更多个不同的分子彼此离解，或者是通过共价或非共价键形成的复合物中的多个分子。对于蛋白质的抗原和佐剂，它们可以作为经皮基因免疫的多核苷酸提供在制剂中。除了液体制剂的简单应用之外，可以使用贴片或其他医疗装置来递送用于免疫的抗原。

2. 发明授权

US5910306A Transdermal delivery system for antigen 失效
标题翻译：用于抗原的透皮递送系统
公开(公告)号：US5910306A
公开(公告)日：1999-06-08
申请号：US749164
申请日：1996-11-14
申请人： Carl R. Alving , Gregory M. Glenn
发明人： Carl R. Alving , Gregory M. Glenn
IPC分类号： A61K9/00 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/127 , A61K9/70 , A61K35/14 , A61K35/39 , A61K39/00 , A61K39/39 , A61P37/04 , A61K39/002 , A61K39/02 , A61K39/12
CPC分类号： A61K39/39 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/127 , A61K9/7023 , A61K2039/54 , A61K2039/55511 , A61K2039/55527 , A61K2039/55544 , A61K2039/55555 , A61K2039/55566 , Y10S424/81 , Y10S424/812
摘要： A transdermal liposome system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses liposomes to deliver a variety of antigens which can elicit an antigen-specific immune response (e.g., humoral and/or cellular effectors) after topical application of a formulation containing liposomes and antigen to intact skin of the animal or human.
摘要翻译：透皮脂质体系统将抗原递送到免疫细胞而不穿透皮肤，并在动物或人体中诱导免疫应答。在将包含脂质体和抗原的制剂局部施用于动物或人的完整皮肤之后，该系统使用脂质体递送各种能够引发抗原特异性免疫应答的抗原（例如体液和/或细胞效应物）。

3. 发明授权

US08911742B2 Transcutaneous immunization without heterologous adjuvant 有权
标题翻译：没有异源佐剂的经皮免疫
公开(公告)号：US08911742B2
公开(公告)日：2014-12-16
申请号：US13348970
申请日：2012-01-12
申请人： Gregory M. Glenn , Carl R. Alving
发明人： Gregory M. Glenn , Carl R. Alving
IPC分类号： A61K39/395 , A61K39/104 , A61K39/116 , A61K39/102 , A61K39/108 , A61K39/02 , A61K39/08 , A61K39/00
CPC分类号： A61K39/08 , A61K39/008 , A61K39/015 , A61K39/0258 , A61K39/05 , A61K39/099 , A61K39/102 , A61K39/104 , A61K39/107 , A61K39/116 , A61K39/12 , A61K2039/5252 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55505 , A61K2039/55522 , A61K2039/55533 , A61K2039/55544 , A61K2039/55555 , A61K2039/55561 , A61K2039/70 , C12N2740/16234 , C12N2760/16134 , C12N2760/16234 , C12N2760/20134 , Y02A50/472 , Y02A50/474
摘要： Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response without the use of a heterologous adjuvant. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigensImmune responses that provide prophylactic and/or therapeutic treatments are preferred. Antigenic activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a dry or liquid formulation to the skin, patches and other medical devices may be used to deliver antigen for immunization.
摘要翻译：经皮免疫可通过角质层将免疫系统的抗原递送到皮肤真皮层，而不会物理或化学渗透到真皮层。该递送系统在不使用异源佐剂的情况下诱导抗原特异性免疫应答。该系统可以在外皮施用含有一种或多种抗原的制剂后诱导抗原特异性免疫应答器，优选提供预防和/或治疗治疗的免疫应答。制剂中的抗原活性可以在相同的分子中发现，两个或更多个不同的分子彼此解离，或者通过共价或非共价键形成的复合物中的多个分子。对于蛋白质的抗原，它们可以作为经皮基因免疫的多核苷酸提供在制剂中。除了干燥或液体制剂对皮肤的简单应用之外，还可以使用贴片和其它医疗装置来递送用于免疫的抗原。

4. 发明授权

US07037499B1 Adjuvant for transcutaneous immunization 失效
标题翻译：佐剂用于经皮免疫
公开(公告)号：US07037499B1
公开(公告)日：2006-05-02
申请号：US09266803
申请日：1999-03-12
申请人： Gregory M. Glenn , Carl R. Alving
发明人： Gregory M. Glenn , Carl R. Alving
IPC分类号： A61K45/00 , A61K47/00
CPC分类号： A61K9/06 , A61K9/08 , A61K9/107 , A61K9/127 , A61K9/7023 , A61K39/39 , A61K2039/53 , A61K2039/54 , A61K2039/55511 , A61K2039/55527 , A61K2039/55544 , A61K2039/55555 , A61K2039/55566 , B82Y5/00
摘要： A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and/or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.
摘要翻译：经皮免疫系统将抗原递送到免疫细胞而不穿透皮肤，并在动物或人体中诱导免疫应答。在将包含抗原和佐剂的制剂经皮施用于动物或人的完整皮肤之后，该系统使用佐剂，优选ADP-核糖基化外毒素来诱导抗原特异性免疫应答（例如体液和/或细胞效应物）。可以通过向经皮递送系统中加入水合剂（例如脂质体），渗透增强剂或闭塞性敷料来增强免疫效率。该系统可以允许激活皮肤中的朗格汉斯细胞，朗格汉斯细胞迁移到淋巴结，以及抗原呈递。

5. 发明授权

US5980898A Adjuvant for transcutaneous immunization 失效
公开(公告)号：US5980898A
公开(公告)日：1999-11-09
申请号：US896085
申请日：1997-07-17
申请人： Gregory M. Glenn , Carl R. Alving
发明人： Gregory M. Glenn , Carl R. Alving
IPC分类号： A61K39/00 , A01N37/18 , A61F13/00 , A61K9/00 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/127 , A61K9/52 , A61K9/56 , A61K9/70 , A61K35/14 , A61K35/39 , A61K39/015 , A61K39/05 , A61K39/08 , A61K39/10 , A61K39/102 , A61K39/104 , A61K39/106 , A61K39/39 , A61P37/00 , A61P37/04 , C07K14/005 , C07K14/195
CPC分类号： A61K9/06 , A61K39/39 , A61K9/08 , A61K9/107 , A61K9/127 , A61K9/7023 , B82Y5/00 , A61K2039/53 , A61K2039/54 , A61K2039/55511 , A61K2039/55527 , A61K2039/55544 , A61K2039/55555 , A61K2039/55566
摘要： A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and/or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.

6. 发明申请

US20120201845A1 TRANSCUTANEOUS IMMUNIZATION WITHOUT HETEROLOGOUS ADJUVANT 有权
标题翻译：没有异位症患者的临床免疫
公开(公告)号：US20120201845A1
公开(公告)日：2012-08-09
申请号：US13348970
申请日：2012-01-12
申请人： Gregory M. Glenn , Carl R. Alving
发明人： Gregory M. Glenn , Carl R. Alving
IPC分类号： A61K39/00 , A61K39/145 , A61K31/7088 , A61P33/00 , A61P31/04 , A61P31/10 , A61P31/16 , A61K39/07 , A61P37/04
CPC分类号： A61K39/08 , A61K39/008 , A61K39/015 , A61K39/0258 , A61K39/05 , A61K39/099 , A61K39/102 , A61K39/104 , A61K39/107 , A61K39/116 , A61K39/12 , A61K2039/5252 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55505 , A61K2039/55522 , A61K2039/55533 , A61K2039/55544 , A61K2039/55555 , A61K2039/55561 , A61K2039/70 , C12N2740/16234 , C12N2760/16134 , C12N2760/16234 , C12N2760/20134 , Y02A50/472 , Y02A50/474
摘要： Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response without the use of a heterologous adjuvant. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigens Immune responses that provide prophylactic and/or therapeutic treatments are preferred. Antigenic activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a dry or liquid formulation to the skin, patches and other medical devices may be used to deliver antigen for immunization.
摘要翻译：经皮免疫可通过角质层将免疫系统的抗原递送到皮肤真皮层，而不会物理或化学渗透到真皮层。该递送系统在不使用异源佐剂的情况下诱导抗原特异性免疫应答。该系统可以在外皮施用含有一种或多种抗原的制剂后诱导抗原特异性免疫效应物优选提供预防和/或治疗性治疗的免疫应答。制剂中的抗原活性可以在相同的分子中发现，两个或更多个不同的分子彼此解离，或者通过共价或非共价键形成的复合物中的多个分子。对于蛋白质的抗原，它们可以作为经皮基因免疫的多核苷酸提供在制剂中。除了干燥或液体制剂对皮肤的简单应用之外，还可以使用贴片和其它医疗装置来递送用于免疫的抗原。

7. 发明申请

US20080063696A1 Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant 有权
标题翻译：使用渗透促进剂和屏障破坏方法来增强抗原和佐剂的免疫应答
公开(公告)号：US20080063696A1
公开(公告)日：2008-03-13
申请号：US10790715
申请日：2004-03-03
申请人： Gregory M. Glenn , Carl R. Alving
发明人： Gregory M. Glenn , Carl R. Alving
IPC分类号： A61K48/00 , A61K39/395 , A61K39/00 , A61K31/739 , A61K38/19
CPC分类号： A61K9/0014 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/127 , A61K9/7023 , A61K31/739 , A61K35/74 , A61K39/00 , A61K39/008 , A61K39/0258 , A61K39/05 , A61K39/102 , A61K39/107 , A61K39/12 , A61K39/145 , A61K39/205 , A61K39/39 , A61K47/08 , A61K47/10 , A61K47/12 , A61K2039/53 , A61K2039/54 , A61K2039/55505 , A61K2039/55511 , A61K2039/55522 , A61K2039/55533 , A61K2039/55544 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , A61K2039/70 , C12N2740/16234 , C12N2760/16034 , C12N2760/20134 , Y02A50/472 , Y02A50/474
摘要： A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.
摘要翻译：经皮免疫系统，其中局部施用佐剂和编码抗原的抗原或核酸到完整的皮肤诱导全身或粘膜炎抗体应答。如此引发的免疫应答可以通过物理或化学皮肤渗透增强来增强。

8. 发明授权

US06797276B1 Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response 有权
标题翻译：使用渗透促进剂和屏障破坏剂来增强经皮免疫反应
公开(公告)号：US06797276B1
公开(公告)日：2004-09-28
申请号：US09257188
申请日：1999-02-25
申请人： Gregory M. Glenn , Carl R. Alving
发明人： Gregory M. Glenn , Carl R. Alving
IPC分类号： A61K4500
CPC分类号： A61K9/0014 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/127 , A61K9/7023 , A61K31/739 , A61K35/74 , A61K39/00 , A61K39/008 , A61K39/0258 , A61K39/05 , A61K39/102 , A61K39/107 , A61K39/12 , A61K39/145 , A61K39/205 , A61K39/39 , A61K47/08 , A61K47/10 , A61K47/12 , A61K2039/53 , A61K2039/54 , A61K2039/55505 , A61K2039/55511 , A61K2039/55522 , A61K2039/55533 , A61K2039/55544 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , A61K2039/70 , C12N2740/16234 , C12N2760/16034 , C12N2760/20134 , Y02A50/472 , Y02A50/474
摘要： A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a ystemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.
摘要翻译：经皮免疫系统，其中局部施用佐剂和编码抗原的抗原或核酸到完整的皮肤诱导全身或粘膜抗体应答。如此引发的免疫应答可以通过物理或化学皮肤渗透增强来增强。

9. 发明授权

US07378097B2 Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant 有权
公开(公告)号：US07378097B2
公开(公告)日：2008-05-27
申请号：US10790715
申请日：2004-03-03
申请人： Gregory M. Glenn , Carl R. Alving
发明人： Gregory M. Glenn , Carl R. Alving
IPC分类号： A61K45/00
CPC分类号： A61K9/0014 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/127 , A61K9/7023 , A61K31/739 , A61K35/74 , A61K39/00 , A61K39/008 , A61K39/0258 , A61K39/05 , A61K39/102 , A61K39/107 , A61K39/12 , A61K39/145 , A61K39/205 , A61K39/39 , A61K47/08 , A61K47/10 , A61K47/12 , A61K2039/53 , A61K2039/54 , A61K2039/55505 , A61K2039/55511 , A61K2039/55522 , A61K2039/55533 , A61K2039/55544 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , A61K2039/70 , C12N2740/16234 , C12N2760/16034 , C12N2760/20134 , Y02A50/472 , Y02A50/474
摘要： A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.

10. 发明授权

US06224902B1 Vaccines against sterols 失效
标题翻译：针对甾醇的疫苗
公开(公告)号：US06224902B1
公开(公告)日：2001-05-01
申请号：US09023256
申请日：1998-02-13
申请人： Carl R. Alving , Julie Kenner , Glenn M. Swartz, Jr. , John W. Madsen
发明人： Carl R. Alving , Julie Kenner , Glenn M. Swartz, Jr. , John W. Madsen
IPC分类号： A61K9127
CPC分类号： A61K31/575 , A61K9/127 , A61K9/1271 , A61K31/58 , A61K31/66 , A61K38/00 , A61K39/00 , A61K39/0002 , A61K39/0012 , A61K39/02 , A61K39/39 , A61K2039/55505 , A61K2039/5555 , A61K2039/55555 , A61K2039/55572 , B82Y5/00 , C07K14/445 , C07K16/1203 , C07K16/18 , C07K16/44 , G01N33/92 , G01N2800/044
摘要： The present invention relates to immunoreactive vaccine compositions for immunizing humans or animals against sterols, such as cholesterol and its derivatives, and their use in methods for reducing the serum cholesterol levels of the immunized individuals and to retard or reduce the severity of artherosclerosis or artherosclerosis plaques caused by ingestion of dietary cholesterol.
摘要翻译：本发明涉及用于免疫人或动物对抗甾醇（例如胆固醇及其衍生物）的免疫反应性疫苗组合物，以及它们在降低免疫个体的血清胆固醇水平的方法中的用途，并且用于延缓或降低动脉粥样硬化或动脉粥样硬化斑块的严重程度由摄入膳食胆固醇引起。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式